NCT00576511已完成2 期
A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Severe Chronic Constipation
Movetis0 个研究点目标入组 53 人开始时间: 1994年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
- 主要终点
- Constipation severity (VAS)
研究概览
简要总结
The purpose of this study is to determine whether prucalopride is safe and effective in patients with severe chronic constipation.
详细描述
This is a phase II trial with a parallel-group design, consisting of a run-in phase (phase I), followed by a placebo controlled double-blind phase (phase 2). Patients will receive either R093877 4 mg or placebo o.d. for a period of 4 weeks.
Phase 1 is a run-in period of 4 weeks duration, during which the bowel habit is documented and the existence of constipation determined. If the definition of constipation was not met during the 4 weeks of the run-in period, double-blind treatment will not be started.
Phase 2 is a double-blind, randomized, placebo-controlled phase, in which patients will be treated for 4 weeks with either 4 mg of R093877 or placebo given o.d. (two capsules of 2 mg are taken before breakfast).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients were eligible for inclusion if they were aged 18-75 years with a history of constipation, defined as the occurrence 2 of the following criteria during the previous 6 months or more:
- •2 spontaneous (i.e. not induced by a laxative within 24 hours) bowel movements per week;
- •25% of stools were lumpy and/or hard;
- •sensation of incomplete evacuation following 25% of stool;
- •straining at defaecation for 25% of the time.
- •All the patients screened for the study were dependent on osmotic laxatives (macrogol, milk of magnesia, lactulose), paraffin oil, glycerol or stimulant laxatives (antranoids, diphenylmethanes) given orally or rectally. The osmotic laxatives were taken on a daily base while the stimulant laxatives were restricted to 2, eventually 3 intakes per week. And although these laxatives, all or not combined promoted defaecation in the majority of patients, these regimens did not provide relief of constipation symptoms in none of the patients. Furthermore, many patients reported that the effect of the laxatives declined over time, that the intake of even stimulant laxatives was not consistently followed by rectal evacuation or that the intake of even stimulant laxatives was not consistently followed by rectal evacuation of that the dose and frequency of intake of laxatives had to be limited because of intolerable side effects including vomiting and abdominal cramps.
- •Eligible patients were also required to have constipation causing disability, with the patient's occupational, social and recreational activities governed by constipation and efforts to attain relief, and to have poor results with laxative treatment and diet counseling as determined by physician interview.
- •Patients also had to have a normal electromyographic inhibition pattern of the external anal sphincter during straining (assessed at the start of the treatment phase) and an absence of organic abnormalities of the colon (as assessed by barium enema or total colonoscopy).
排除标准
- •Drug-induced constipation
- •Secondary causes of constipation
- •Known or suspected organic large bowel disorders
- •Congenital or acquired megacolon/megarectum
- •History of previous abdominal surgery
- •Evidence of a non-relaxing pelvic floor as the main cause of constipation
- •Active proctological conditions
- •Impaired renal function or clinically significant abnormalities of blood chemistry, hematology, urinalysis or ECG.
- •Patients who were pregnant, breast feeding, not using acceptable methods of birth control or who had known illnesses or conditions that might interfere with adequate assessment of the study drug were also excluded.
研究组 & 干预措施
1
Active Comparator
Prucalopride
干预措施: prucalopride (Drug)
2
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Constipation severity (VAS)
时间窗: 4 weeks
次要结局
- Stool frequency (stool/week)(4 weeks)
研究者
相似试验
已完成
3 期
Efficacy and Safety Study of Prucalopride for the Treatment of Elderly Patients With Chronic ConstipationConstipationNCT00487422Movetis303
已完成
2 期
Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing FacilityConstipationNCT00627692Movetis100
已完成
3 期
Efficacy and Safety Study of Prucalopride for the Treatment of Patients With Chronic ConstipationConstipationNCT00485940Movetis641
已完成
3 期
Efficacy and Safety Study of Prucalopride to Treat Chronic ConstipationConstipationNCT00488137Movetis716
已完成
3 期
Efficacy and Safety Study of Prucalopride for the Treatment of Chronic ConstipationConstipationNCT00483886Movetis620